Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.

Gunderson CC, Fader AN, Carson KA, Bristow RE.

Gynecol Oncol. 2012 May;125(2):477-82. doi: 10.1016/j.ygyno.2012.01.003. Review.

PMID:
22245711
2.

Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review.

Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C.

Gynecol Oncol. 2004 Oct;95(1):133-8. Review.

PMID:
15385122
3.
4.

Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.

Ohyagi-Hara C, Sawada K, Aki I, Mabuchi S, Kobayashi E, Ueda Y, Yoshino K, Fujita M, Tsutsui T, Kimura T.

Arch Gynecol Obstet. 2015 Jan;291(1):151-7. doi: 10.1007/s00404-014-3417-z. Review.

PMID:
25118836
5.

[Endometrial adenocarcinoma in women 40 years old or younger by treatment with progestins: report of 6 cases and review of the literatures].

Wang HY, Shen L, Sun Z.

Zhonghua Fu Chan Ke Za Zhi. 2006 Apr;41(4):237-41. Review. Chinese.

PMID:
16759457
6.

Conservative management of patients with early endometrial carcinoma: a systematic review.

Chiva de Agustín L, Lapuente Sastre F, Corraliza Galán V, Granados Galainena L, González Martín A, González Cortijo L, Carballo González N.

Clin Transl Oncol. 2008 Mar;10(3):155-62. Review.

PMID:
18321818
7.

Sparing fertility in young patients with endometrial cancer.

Chiva L, Lapuente F, González-Cortijo L, Carballo N, García JF, Rojo A, Gonzalez-Martín A.

Gynecol Oncol. 2008 Nov;111(2 Suppl):S101-4. doi: 10.1016/j.ygyno.2008.07.056. Review.

PMID:
18804267
8.

Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer.

Park JY, Nam JH.

Oncologist. 2015 Mar;20(3):270-8. doi: 10.1634/theoncologist.2013-0445. Review.

9.

Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature.

Kim YB, Holschneider CH, Ghosh K, Nieberg RK, Montz FJ.

Cancer. 1997 Jan 15;79(2):320-7. Review.

PMID:
9010105
10.

Conservative management of young women with endometrial carcinoma or complex atypical hyperplasia: report of three cases and literature review.

Karimi-Zarchi M, Mousavi AS, Behtash N, Chiti Z, Bokaie M.

Eur J Gynaecol Oncol. 2011;32(6):695-8. Review.

PMID:
22335041
11.

Conservative management of young patients with endometrial highly-differentiated adenocarcinoma.

Kalogiannidis I, Agorastos T.

J Obstet Gynaecol. 2011;31(1):13-7. doi: 10.3109/01443615.2010.532249. Review.

PMID:
21280986
12.

Conservative treatment of early endometrial cancer.

Bovicelli A, D'Andrilli G, Giordano A, De Iaco P.

J Cell Physiol. 2013 Jun;228(6):1154-8. doi: 10.1002/jcp.24292. Review.

PMID:
23172641
13.

Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer.

Gotlieb WH, Beiner ME, Shalmon B, Korach Y, Segal Y, Zmira N, Koupolovic J, Ben-Baruch G.

Obstet Gynecol. 2003 Oct;102(4):718-25. Review.

PMID:
14551001
14.

The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option.

Gadducci A, Spirito N, Baroni E, Tana R, Genazzani AR.

Gynecol Endocrinol. 2009 Oct;25(10):683-91. doi: 10.1080/09513590902733733. Review.

PMID:
19562604
15.

Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis.

Koskas M, Uzan J, Luton D, Rouzier R, Daraï E.

Fertil Steril. 2014 Mar;101(3):785-94. doi: 10.1016/j.fertnstert.2013.11.028. Review.

PMID:
24388202
16.

The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer.

Lai CH, Huang HJ.

Curr Opin Obstet Gynecol. 2006 Feb;18(1):29-34. Review.

PMID:
16493257
17.

Endometrial cancer.

Arora V, Quinn MA.

Best Pract Res Clin Obstet Gynaecol. 2012 Jun;26(3):311-24. doi: 10.1016/j.bpobgyn.2011.12.007. Review.

PMID:
22277287
18.

Clinical response of abnormal endometrial growth to hormonal treatment.

López de la Osa González E.

Ann N Y Acad Sci. 1994 Sep 30;734:306-9. Review.

PMID:
7978931
19.

Endometrial carcinoma remaining after term pregnancy following conservative treatment with medroxyprogesterone acetate.

Mitsushita J, Toki T, Kato K, Fujii S, Konishi I.

Gynecol Oncol. 2000 Oct;79(1):129-32. Review.

PMID:
11006045
20.

Fertility-sparing therapy for young women with endometrial cancer.

Frumovitz M, Gershenson DM.

Expert Rev Anticancer Ther. 2006 Jan;6(1):27-32. Review.

PMID:
16375641
Items per page

Supplemental Content

Support Center